{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:22:41Z","timestamp":1791465761981,"version":"4.3.4"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T00:00:00Z","timestamp":1717113600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T00:00:00Z","timestamp":1717113600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-024-03048-3","type":"journal-article","created":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T12:02:27Z","timestamp":1717156947000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Increased presentation for vitiligo cutaneous immune related adverse events in Hispanic patients"],"prefix":"10.1007","volume":"316","author":[{"given":"Zoha K.","family":"Momin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer G.","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan","family":"Heberton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,31]]},"reference":[{"issue":"3","key":"3048_CR1","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1080\/09546634.2021.1898529","volume":"33","author":"TK Le","year":"2022","unstructured":"Le TK, Kaul S, Cappelli LC, Naidoo J, Semenov YR, Kwatra SG (2022) Cutaneous adverse events of immune checkpoint inhibitor therapy: incidence and types of reactive dermatoses. J Dermatolog Treat May 33(3):1691\u20131695. https:\/\/doi.org\/10.1080\/09546634.2021.1898529","journal-title":"J Dermatolog Treat May"},{"issue":"5","key":"3048_CR2","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.jaad.2020.03.132","volume":"83","author":"AN Geisler","year":"2020","unstructured":"Geisler AN, Phillips GS, Barrios DM et al (2020) Immune checkpoint inhibitor-related dermatologic adverse events. J Am Acad Dermatol Nov 83(5):1255\u20131268. https:\/\/doi.org\/10.1016\/j.jaad.2020.03.132","journal-title":"J Am Acad Dermatol Nov"},{"key":"3048_CR3","doi-asserted-by":"publisher","unstructured":"Wongvibulsin S, Pahalyants V, Kalinich M et al (Mar 2022) Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: a United States population-level analysis. J Am Acad Dermatol 86(3):563\u2013572. https:\/\/doi.org\/10.1016\/j.jaad.2021.03.094","DOI":"10.1016\/j.jaad.2021.03.094"},{"issue":"3","key":"3048_CR4","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.jaad.2020.09.096","volume":"84","author":"LL Thompson","year":"2021","unstructured":"Thompson LL, Pan CX, Chang MS, Krasnow NA, Blum AE, Chen ST (2021) Impact of ethnicity on the diagnosis and management of cutaneous toxicities from immune checkpoint inhibitors. J Am Acad Dermatol Mar 84(3):851\u2013854. https:\/\/doi.org\/10.1016\/j.jaad.2020.09.096","journal-title":"J Am Acad Dermatol Mar"},{"issue":"30","key":"3048_CR5","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1200\/jco.18.02141","volume":"20","author":"GS Phillips","year":"2019","unstructured":"Phillips GS, Wu J, Hellmann MD et al (2019) Treatment outcomes of Immune-related cutaneous adverse events. J Clin Oncol Oct 20(30):2746\u20132758. https:\/\/doi.org\/10.1200\/jco.18.02141","journal-title":"J Clin Oncol Oct"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03048-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-024-03048-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03048-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T11:38:35Z","timestamp":1719401915000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-024-03048-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,31]]},"references-count":5,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["3048"],"URL":"https:\/\/doi.org\/10.1007\/s00403-024-03048-3","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,31]]},"assertion":[{"value":"3 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Heberton (M.H.) has served on an advisory board for Blueprint Medicines, which is not relevant to any of the work in this publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"293"}}